Invention Grant
![Substituted pyrrolo[2,3-B]pyrazine compounds and their use](/docs/US/2015-01-20/US08937069B2/abs.jpg.600x600.jpg)
- Patent Title: Substituted pyrrolo[2,3-B]pyrazine compounds and their use
- Patent Title (中): 取代的吡咯并[2,3-B]吡嗪化合物及其用途
-
Application No.: US13739302Application Date: 2013-01-11
-
Publication No.: US08937069B2Publication Date: 2015-01-20
- Inventor: Claire Adcock , Catherine Leblanc
- Applicant: Novartis AG
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- Agent Rona Nardone
- Main IPC: A61K31/4985
- IPC: A61K31/4985 ; C07D487/04 ; A61K45/06
![Substituted pyrrolo[2,3-B]pyrazine compounds and their use](/abs-image/US/2015/01/20/US08937069B2/abs.jpg.150x150.jpg)
Abstract:
The present invention provides compounds of formula (Ia) and (Ib) which activate the IP receptor, processes for preparing them, pharmaceutical compositions comprising said compounds and uses thereof. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients.
Public/Granted literature
- US20130184282A1 IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS Public/Granted day:2013-07-18
Information query
IPC分类:
